Should I Buy ATNM? ATNM 2026 Analysis

Should You Buy Actinium Pharmaceuticals Inc (ATNM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.230

1 Day change

0.82%

52 Week Range

2.410

Analysis Updated At

2026/01/28

ATNM is not a good buy right now for a beginner long-term investor with $50k–$100k who wants to act immediately. The trend is bearish (all key moving averages stacked bearishly), momentum is weak, there are no near-term news catalysts, and the latest quarter shows widening losses. Options positioning is extremely call-heavy, which looks more like speculative risk-on sentiment than a stable long-term setup at this moment.

Technical Analysis

Price/Trend: Bearish. The moving averages are stacked down (SMA_200 > SMA_20 > SMA_5), signaling a sustained downtrend. Momentum: MACD histogram is negative (-0.00745) and still below zero (bearish), though contracting (downside momentum is easing but not reversed). RSI(6)=40.17 is neutral-to-weak, not oversold enough to suggest a strong bounce. Key levels: Pivot 1.317. Support S1 1.271 then S2 1.243. Resistance R1 1.363 then R2 1.391. With pre-market ~1.28, price is sitting near S1; a clean break below 1.271 increases downside risk. Pattern-based short-term odds: Similar-pattern stats imply mild negative drift (-1.36% next week, -2.93% next month). Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment: Extremely call-skewed. Put open interest is tiny (28) versus call open interest (4,333), yielding an OI put/call ratio of 0.01, and today’s put volume is 0 (volume put/call ratio 0.0). This reflects aggressive bullish/speculative positioning. Volatility: Very high risk pricing—30D IV ~210% vs historical vol ~81.5%. IV is elevated (IV percentile ~64.8). This typically implies the market expects large moves and makes options expensive; it also often aligns with “event hope” rather than confirmed fundamentals. Activity: Today’s option volume (358) is well above the 30-day average (~190% of average), reinforcing heightened speculative interest.

Technical Summary

Sell

Buy

Positive Catalysts

No news in the last week, so no clear event-driven catalyst identified.
Possible supportive factors from the tape: very strong call-heavy options positioning (OI and volume), which can sometimes precede volatility to the upside if a catalyst appears.
If the company releases favorable clinical/regulatory updates (typical biotech catalyst), sentiment could shift quickly—however, none is indicated in the provided data.

Neutral/Negative Catalysts

No recent news flow (lack of catalysts) while the chart remains in a downtrend.
Bearish technical structure (SMA_200 > SMA_20 > SMA_5) and negative MACD.
High implied volatility (210%) signals elevated uncertainty and unstable pricing.
Short-term pattern statistics skew negative for the next week/month.
No supportive “smart money” trend indicated: hedge funds and insiders are both neutral in the provided trend summary.
No recent congress trading data available (no signal of influential buying).

Financial Performance

Latest quarter: 2025/Q3. Revenue was $90,000 (flat YoY). Profitability worsened: Net income fell to -$5.131M (down 55.64% YoY) and EPS to -0.16 (down 56.76% YoY). Gross margin shows as 100 (unchanged), but the core takeaway is widening losses with minimal revenue—typical of a high-risk development-stage profile and not ideal for a beginner long-term allocation right now.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so a recent trend summary cannot be confirmed from the dataset. Wall Street-style pros: biotech optionality (potential upside on clinical/regulatory wins), and recent options market call-skew suggests some traders are positioned for upside. Wall Street-style cons: weak/declining earnings profile (larger losses), minimal current revenue base, high volatility/uncertainty (very high IV), and a clearly bearish technical trend.

3 Analyst Rating

Wall Street analysts forecast ATNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATNM is 6 USD with a low forecast of 4 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.220

Low

Averages

High

Current: 1.220

Low

Averages

High

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

AI Analysis

2025-04-01

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

AI Analysis

2025-04-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2025-03-27

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2025-03-27

Reiterates

Strong Buy

Reason

ATNM Should I Buy

ATNM Should I Buy

Should You Buy Actinium Pharmaceuticals Inc (ATNM) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch